{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 49 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '8.', 'INFORMED CONSENT, TRIAL RECORDS, DATA', 'PROTECTION, PUBLICATION POLICY, AND', 'ADMINISTRATIVE STRUCTURE', 'The trial will be carried out in compliance with the protocol, the ethical principles laid down', 'in the Declaration of Helsinki, in accordance with the ICH Harmonized Tripartite Guideline', 'for Good Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs),', 'Standard medical care (prophylactic, diagnostic and therapeutic procedures) remains the', 'responsibility of the treating physician of the patient.', 'The investigator will inform the sponsor immediately of any urgent safety measures taken to', 'protect the trial patients against any immediate hazard, as well as of any serious breaches of', 'the protocol or of ICH GCP.', 'The Boehringer Ingelheim transparency and publication policy can be found on the following', 'web page: rials.boehringer-ingelheim.com The rights of the investigator and of the sponsor', 'with regard to publication of the results of this trial are described in the investigator contract.', 'As a rule, no trial results should be published prior to finalization of the Clinical Trial Report.', '8.1', 'TRIAL APPROVAL, PATIENT INFORMATION, INFORMED CONSENT', 'This trial will be initiated only after all required legal documentation has been reviewed and', 'approved by the respective Institutional Review Board (IRB) / Independent Ethics Committee', '(IEC) and competent authority (CA) according to national and international regulations. The', 'same applies for the implementation of changes introduced by amendments.', 'Prior to patient participation in the trial, written informed consent must be obtained from each', \"patient (or the patient's legally accepted representative) according to ICH / GCP and to the\", 'regulatory and legal requirements of the participating country. Each signature must be', 'personally dated by each signatory and the informed consent and any additional patient-', 'information form retained by the investigator as part of the trial records. A signed copy of the', 'informed consent and any additional patient information must be given to each patient or the', 'patient\\'s legally accepted representative.\"', 'The investigator must give a full explanation to trial patients based on the patient information', 'form. A language understandable to the patient should be chosen, technical terms and', 'expressions avoided, if possible.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 50 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'The patient must be given sufficient time to consider participation in the trial. The', \"investigator obtains written consent of the patient's own free will with the informed consent\", 'form after confirming that the patient understands the contents. Re-consenting may become', 'necessary when new relevant information becomes available and should be conducted', \"according to the sponsor's instructions.\", 'The consent and re-consenting process should be properly documented in the source', 'documentation.', '8.2', 'DATA QUALITY ASSURANCE', \"A quality assurance audit/inspection of this trial may be conducted by the sponsor, sponsor's\", 'designees, or by IRB / IEC or by regulatory authorities. The quality assurance auditor will', \"have access to all medical records, the investigator's trial-related files and correspondence,\", 'and the informed consent documentation of this clinical trial.', '8.3', 'RECORDS', 'CRFs for individual patients will be provided by the sponsor.', '8.3.1', 'Source documents', 'In accordance with regulatory requirements the investigator should prepare and maintain', 'adequate and accurate source documents and trial records that include all observations and', 'other data pertinent to the investigation on each trial patient. Source data as well as reported', 'data should follow good documentation practices and be attributable, legible,', 'contemporaneous, original and accurate. Changes to the data should be traceable (audit trail).', 'Data reported on the CRF must be consistent with the source data or the discrepancies must', 'be explained.', 'The current medical history of the patient may not be sufficient to confirm eligibility for the', 'trial and the investigator may need to request previous medical histories and evidence of any', 'diagnostic tests. In this case the investigator must make three documented attempts to retrieve', 'previous medical records. If this fails a verbal history from the patient, documented in their', 'medical records, would be acceptable.', \"During the site visit the sponsor's CRA or auditor must be granted access to the original\", 'patient file (please see section 8.3.2). The investigator must ensure that all patient identifiers', \"(e.g. patient's name, initials, address, phone number, social security number) have properly\", \"been removed or redacted from any copy of the patients' source documents before sending\", 'them to the sponsor.', 'If the patient is not compliant with the protocol, any corrective action e.g. re-training must be', 'documented in the patient file', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}